Ryvu Therapeutics Announces Project Updates at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Current TAP Partner
Krakow, Poland – April 27, 2022 – Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, today announced project updates from its most advanced oncology program RVU120 and a selective PIM/FLT3 inhibitor SEL24 (MEN1703) will be made available at the 2022 ASCO Annual Meeting, taking place June 3-7 in Chicago, IL, U.S.
Update details:
- Title: Phase 1/2 study of SEL24/MEN1703, a first-in-class dual PIM/FLT3 kinase inhibitor, in patients with IDH1/2-mutated acute myeloid leukemia: The DIAMOND-01 trial
Abstract Number for Publication: 7024
Session Title: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Session Date and Time: Saturday, June 4, 2022, 8:00 AM-11:00 AM CDT
- Title: Phase I/II trial of RVU120 (SEL120), a CDK8/CDK19 inhibitor in patients with relapsed/refractory metastatic or advanced solid tumors
Abstract Number for Online Publication: e15091
The full texts of ASCO Abstracts will be released on May 26 at 5:00 PM (EDT)/(23:00 CET).